A Clinical Trial of Sacituzumab Tirumotecan (MK-2870) for Bladder Cancer
Phase 1/2
32
about 3.6 years
18+
4 sites in CA, FL, IL +1
What this study is about
This trial is testing the safety and tolerability of Sacituzumab Tirumotecan in people with bladder cancer. Researchers will determine the highest dose that can be safely administered to participants. Its length is 1319 days.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Rescue medication
- 2.Take Sacituzumab tirumotecan
- 3.Take Supportive care measures
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Primary: Number of Participants Discontinuing Study Treatment due to an Adverse Event (AE), Number of Participants Experiencing an Adverse Event (AE), Number of Participants with Dose Limiting Toxicity (DLT)
Secondary: Area Under the Serum Concentration-Time Curve (AUC) of sacituzumab tirumotecan (sac-TMT) Antibody-Drug Conjugate (ADC), Complete Response Rate (CRR), Duration of Complete Response (DCR), Maximum Serum Concentration (Cmax) of sac-TMT ADC, Plasma AUC of sac-TMT payload, Plasma Cmax of sac-TMT payload, Serum AUC of sac-TMT Total Antibody (TAb), Serum Apparent terminal half-life (t½) of sac-TMT ADC
Oncology